• Publications
  • Influence
Impaired PGC-1alpha function in muscle in Huntington's disease.
We investigated the role of PPAR gamma coactivator 1alpha (PGC-1alpha) in muscle dysfunction in Huntington's disease (HD). We observed reduced PGC-1alpha and target genes expression in muscle of HDExpand
  • 194
  • 11
Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer's disease model via canonical Wnt/β-catenin pathway.
Neurogenesis, a process of generation of new neurons, is reported to be reduced in several neurodegenerative disorders including Alzheimer's disease (AD). Induction of neurogenesis by targetingExpand
  • 278
  • 9
Mitochondrial diseases of the brain.
Neurodegenerative disorders are debilitating diseases of the brain, characterized by behavioral, motor and cognitive impairments. Ample evidence underpins mitochondrial dysfunction as a centralExpand
  • 301
  • 9
Mitochondrial Approaches for Neuroprotection
A large body of evidence from postmortem brain tissue and genetic analysis in humans and biochemical and pathological studies in animal models (transgenic and toxin) of neurodegeneration suggest thatExpand
  • 231
  • 8
  • PDF
PPAR: a therapeutic target in Parkinson’s disease
Parkinson’s disease (PD) is a progressive and chronic neurodegenerative disorder, characterized by progressive loss of dopaminergic neurons in substantia nigra. The etiology and pathogenesis of PD isExpand
  • 123
  • 7
Ginkgo biloba affords dose‐dependent protection against 6‐hydroxydopamine‐induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences
Ginkgo biloba extract (EGb), a potent antioxidant and monoamine oxidase B (MAO‐B) inhibitor, was evaluated for its anti‐parkinsonian effects in a 6‐hydroxydopamine (6‐OHDA) rat model of the disease.Expand
  • 127
  • 6
Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.
We investigated the ability of AMP-activated protein kinase (AMPK) to activate PPARgamma coactivator-1alpha (PGC-1alpha) in the brain, liver and brown adipose tissue (BAT) of the NLS-N171-82QExpand
  • 116
  • 5
Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders.
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors and they serve to be a promising therapeutic target for several neurodegenerative disorders, which includes ParkinsonExpand
  • 85
  • 5
Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease
In the present study, an attempt has been made to explore the neuroprotective and neuroreparative (neurorescue) effect of black tea extract (BTE) in 6-hydroxydopamine (6-OHDA)-lesioned rat model ofExpand
  • 93
  • 5
Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease
Caused by a polyglutamine expansion in the huntingtin protein, Huntington's disease leads to striatal degeneration via the transcriptional dysregulation of a number of genes, including those involvedExpand
  • 121
  • 4
  • PDF